



IFW

PATENT
Customer Number: 22,852
Attorney Docket No. 07705.0001-01000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
ZAMBROWICZ et al.)	Group Art Unit: 1632
)	
Application No.: 10/797,613)	Examiner: Not Yet Assigned
)	
Filed: March 9, 2004)	Confirmation No. 3971
)	
For: VECTORS FOR GENE)	
MUTAGENESIS AND GENE)	
DISCOVERY)	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents listed on the attached IDS Form PTO/SB/08. This Information Disclosure Statement is being filed, to the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.
Copies of the listed U.S. patents are not enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: January 31, 2005

By: 

Rebecca B. Scarr
Reg. No. 47,057
Customer No. 22,852

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/797,613
Filing Date	March 9, 2004
First Named Inventor	ZAMBROWICZ et al.
Art Unit	1632
Examiner Name	Not Yet Assigned
Attorney Docket Number	07705.0001-01000

Sheet 1 of 2

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-6,776,988 B2	08-17-2004	Zambrowicz et al.	
		US-6,808,921 B1	10-26-2004	Zambrowicz et al.	


Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		CA 2,274,092	03-25-2003	Von Melchner		
		WO 96/29411	09-26-1996	Treco et al.		
		WO 98/07858	02/26/1998	Randazzo		
		WO 98/14614	04-09-1998	Sands et al.		
		WO 99/07389	02-18-1999	Burgess et al.		
		WO 00/31236	06-02-2000	Zambrowicz et al.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		Cummings et al., "Genetically lean mice result from targeted disruption of the RII β subunit of protein kinase A," <i>Nature</i> , 382:622-626 (1996).	
		Kappel et al., "Regulating gene expression in transgenic animals," <i>Curr. Opin. Biotech.</i> , 3:548-553 (1992).	
		MacGregor et al., "Tissue non-specific alkaline phosphatase is expressed in both embryonic and extraembryonic lineages during mouse embryogenesis but is not required for migration of primordial germ cells," <i>Development</i> , 121:1487-1496 (1995).	
		Melton, "Gene targeting in the mouse," <i>BioEssays</i> , 16:633-638 (1994).	
		Shivdasani, "The role of transcription factor NF-E2 in megakaryocyte maturation and platelet production," <i>Stem Cells</i> , 14 Suppl 1:112-115 (1996).	
		Sigmund, "Viewpoint: are studies in genetically altered mice out of control?" <i>Arterioscler. Thromb. Vasc. Biol.</i> , 20:1425-1429 (2000).	
		Office Action dated July 17, 2001, in U.S. Patent Application No. 09/570,923, filed May 15, 2000.	
		Response filed September 17, 2001, in U.S. Patent Application No. 09/570,923, filed May 15, 2000.	
		Office Action dated December 6, 2001, in U.S. Patent Application No. 09/570,923, filed May 15, 2000.	
		Amendment Under 37 C.F.R. § 1.111 filed May 6, 2002, in U.S. Patent Application No. 09/570,923, filed May 15, 2000.	
		Office Action dated July 15, 2002, in U.S. Patent Application No. 09/570,923, filed May 15, 2000.	
		Amendment Under 37 C.F.R. § 1.116 filed October 15, 2002, in U.S. Patent Application No. 09/570,923, filed May 15, 2000.	
		Advisory Action dated November 14, 2002, in U.S. Patent Application No. 09/570,923, filed May 15, 2000.	

**Complete if Known**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2	Application Number	10/797,613
-------	---	----	---	--------------------	------------

Filing Date	March 9, 2004
First Named Inventor	ZAMBROWICZ et al.
Art Unit	1632
Examiner Name	Not Yet Assigned
Attorney Docket Number	07705.0001-01000

NON PATENT LITERATURE DOCUMENTS

	Office Action dated March 10, 2003, in U.S. Patent Application No. 09/570,923, filed May 15, 2000.	
	Amendment and Response filed September 10, 2003, in U.S. Patent Application No. 09/570,923, filed May 15, 2000.	
	Office Action dated December 18, 2003, in U.S. Patent Application No. 09/570,923, filed May 15, 2000.	
	Amendment and Response filed April 15, 2004, in U.S. Patent Application No. 09/570,923, filed May 15, 2000.	
	Advisory Action dated May 12, 2004, in U.S. Patent Application No. 09/570,923, filed May 15, 2000.	
	Office Action dated October 4, 2001, in U.S. Patent Application No. 09/639,453, filed August 15, 2000.	
	Response filed December 4, 2001, in U.S. Patent Application No. 09/639,453, filed August 15, 2000.	
	Office Action dated February 26, 2002, in U.S. Patent Application No. 09/639,453, filed August 15, 2000.	
	Amendment Under 37 C.F.R. § 1.111 filed May 24, 2002, in U.S. Patent Application No. 09/639,453, filed August 15, 2000.	
	Office Action dated May 20, 2003, in U.S. Patent Application No. 09/639,453, filed August 15, 2000.	
	Amendment and Response filed January 6, 2004, in U.S. Patent Application No. 09/639,453, filed August 15, 2000.	
	Advisory Action dated January 21, 2004, in U.S. Patent Application No. 09/639,453, filed August 15, 2000.	
	Office Action dated March 10, 2004, in U.S. Patent Application No. 09/639,453, filed August 15, 2000.	
	Amendment and Response filed June 10, 2004, in U.S. Patent Application No. 09/639,453, filed August 15, 2000.	
	Notice of Allowance and Fee(s) Due dated September 27, 2004, in U.S. Patent Application No. 09/639,453, filed August 15, 2000.	
	Office Action dated December 17, 2004, in U.S. Patent Application No. 10/359,033, filed February 4, 2003.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.